Inovio Pharmaceuticals (FRA:GBM) Total Liabilities : €31.90 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Inovio Pharmaceuticals Total Liabilities?

Inovio Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €31.90 Mil.

Inovio Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 (€51.48 Mil) to Dec. 2023 (€49.15 Mil) and declined from Dec. 2023 (€49.15 Mil) to Mar. 2024 (€31.90 Mil).

Inovio Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€85.20 Mil) to Dec. 2022 (€119.11 Mil) but then declined from Dec. 2022 (€119.11 Mil) to Dec. 2023 (€49.15 Mil).

Inovio Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Inovio Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Total Liabilities Chart

Inovio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

124.69

64.64

85.20

119.11

49.15

Inovio Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															62.92	58.76	51.48	49.15	31.90

Inovio Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Inovio Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	39.037	+	(10.116	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	49.15

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	156.762	-	107.609
	=	49.15

Inovio Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	21.529	+	(10.369	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	31.90

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	118.785	-	86.887
	=	31.90

Inovio Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Inovio Pharmaceuticals (FRA:GBM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (FRA:GBM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

INO:USA INO:Mexico

Address

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462

Website

https://www.inovio.com

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Inovio Pharmaceuticals (FRA:GBM) Headlines

No Headlines